Skip to main content

Table 3 Incidence of adverse events

From: Efficacy of AS versus SOX regimen as first-line chemotherapy for gastric cancer patients with peritoneal metastasis: a real-world study

Event

AS group (n = 62)

SOX group (n = 81)

p-Value

Grade1/2

Grade3/4

Grade1/2

Grade3/4

Leukocytopenia

3 (4.84%)

3 (4.84%)

2 (2.47%)

N/A

0.0800

Anemia

2 (3.23%)

N/A

1 (1.23%)

N/A

0.4207

Thrombocytopenia

1 (1.61%)

1 (1.61%)

5 (6.17%)

N/A

0.4000

Vomiting

2 (3.23%)

N/A

3 (3.70%)

N/A

0.8816

Diarrhea

2 (3.23%)

N/A

2 (2.47%)

N/A

0.7915

Hepatic dysfunction

1 (1.61%)

N/A

1 (1.23%)

N/A

0.8507

Peripheral neurotoxicity

3 (4.84%)

N/A

2 (2.47%)

N/A

0.5611

Hand-foot syndrome

3 (4.84%)

N/A

2 (2.47%)

N/A

0.5611

Alopecia

3 (4.84%)

N/A

2 (2.47%)

N/A

0.5611